H2020Individual fellowship2016–2018

HeartAtaK · Targeting the Anti-Target: From Structure to Drug in the heart Kv11.1 channel

Horizon 2020 — Marie Skłodowska-Curie Actions

Duration
2016-09-01 → 2018-08-31
EU contribution
€183,455
Participants
1
Scheme
MSCA-IF

Lines connect the coordinator with its partners.

Results in brief

Targeting the Anti-Target: From Structure to Drug in the heart Kv11.1 channel

One of the world’s biggest secrets is still the functioning of the human brain. In particular, the development of synapses and neuronal activity is a fundamental process about which we still know very little. In terms of their malfunctioning in neurological disorders, our knowledge is even more scarce as the clinical presentation can be very diverse and patients can display very different symptoms even though they have the same diagnosis as for example very often seen for autism spectrum disorder (ASD). Symptoms of ASD can include, in different levels of severity, deficits in verbal and non-verbal communication, mental retardation, lack of social interaction and patterns of stereotypical behaviour. Whole genome sequencing of patients having ASD revealed that 1% of the patients have a mutation in a gene called patched domain-containing protein 1 (ptchd1). Vice versa, 40% of people having a mutation in ptchd1 develop ASD. Thus, ptchd1 is the important marker gene for mental retardation. However, so far very little is known about the function of ptchd1. The protein is supposed to be a receptor in the hedgehog signalling pathway, a pathway best known for its involvement in the prenatal development and the distinction of body patterns. Thus, a defect gene in this signalling pathway has severe consequences for the individual. During this fellowship, I want to investigate how the signal is received by the receptor and how it is transferred to downstream effectors. To achieve this, one aim of this project is to solve the structure of ptchd1 by cryo-EM. The three-dimensional structure of a protein provides the basis for its function. Understanding the protein’s structure allows us to deduce where the incoming signal will bind and how its three-dimensional structure changes upon signalling. However, the signal seems not to be transferred directly from protein to protein but via a small molecule of still unknown identity. As structures provide only static information, I also want to investigate ptchd1’s biophysical behaviour and its interaction with other proteins in order to understand the whole process of signal transduction. This project will provide the first structural information about an important signalling pathway involved in human prenatal development. The information obtained will further shed light a unique signal transfer mechanism.

Data: CORDIS, © European Union

Project objective

Potassium channels are widely distributed and have many important biological functions in the human body. Of special interest is the Kv11.1 channel, whose main function is the repolarization of the membrane after a cardiac action potential. Unfortunately, this channel can be blocked by a variety of structurally diverse drugs causing the long QT syndrome (LQTS), a cardiac repolarization disorder that can lead to arrhythmia and sudden heart death. Due to this very severe side effect, a variety of drugs with otherwise good therapeutic profiles have been withdrawn from the market. Nowadays, cardiac Kv11.1 is an important anti-target in drug development to exclude any potential side effects that could lead to LQTS. In contrast, tumour cells require the expression of specific isoforms of Kv11.1 for survival making these channels a potential anti-cancer drug target – as long as these drugs do not bind to the heart isoform.The major goal of this project is the elucidation of the structure of Kv11.1 via X-ray crystallography or cryo-EM. I have established large-scale protein production of a Kv11.1-chimera using the baculovirus/insect cell expression system, thus enabling biophysical and structural studies to provide structural information on a range of time- and spatial resolution scales. This will not only shed light on the structural motifs responsible for binding a variety of structurally diverse drugs but also improve the fundamental knowledge for the understanding of the special biophysical properties of this channel. By taking these techniques together I will be able to determine how known inhibitors bind, and so identify new isoform specific binding pockets to guide isoform-specific drug design.My career goal is to pursue fundamental and translational research in structural biology of human membrane protein, with a focus on medically important targets and further drug development. This project will bring me closer to that goal.

Original text from CORDIS.

Participants

Links

Data: CORDIS, © European Union